Personalis

126 articles with Personalis

• Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform®

  4/8/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021.

• Personalis Announces Collaboration with MapKure to Use Personalis’ NeXT Platform™ for Clinical Trials and Companion Diagnostic Development

  3/29/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical trial assay (CTA) based on the Personalis ® NeXT Platform™

• Personalis Announces Changes to its Board of Directors

  3/8/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has appointed Dr. Woodrow (Woody) Myers to its Board of Directors and to the Nominating and Corporate Governance Committee of the Board

• Personalis Reports Fourth Quarter and Full Year 2020 Financial Results

  2/25/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020.

• CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

  2/23/2021

  Personalis, Inc., a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021.

• Natera and Personalis Partner for Personalized Monitoring in Oncology

  2/17/2021

  Natera, Inc., a global leader in cell-free DNA testing, and Personalis, Inc., a leader in advanced genomics for cancer, announced that the two companies have entered into a partnership in the field of personalized oncology.

• Personalis to Present at Upcoming Investor Conferences

  2/16/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following upcoming investor conferences:

• Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

  2/11/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021.

• Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer

  2/8/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Susan Moriconi as VP of People and Chief Human Resources Officer.

• Personalis to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

  2/4/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 12:00 p.m. Eastern Time.

• Personalis Announces Pricing of Public Offering of Common Stock - Jan 27, 2021

  1/27/2021

  Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced the pricing of its previously announced underwritten public offering of 3,950,000 shares of its common stock at a price to the public of $38.00 per share.

• Personalis Announces Launch of Public Offering of Common Stock - Jan 26, 2021

  1/26/2021

  Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced that it has commenced an underwritten public offering of $150.0 million of its common stock.

• Personalis Reports Preliminary Fourth Quarter 2020 Revenue

  1/11/2021

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020. Personalis estimates revenue of approximately $20.2 million for the fourth quarter of 2020 compared with $18.2 million in the fourth quarter of 2019, representing an increase of 11%. For the full year 2020, r

• Voyager Therapeutics Announced Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/11/2021

  Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant of a non-qualified stock option and of restricted stock units as inducements material to the employee entering into employment with Voyager. The inducement awards wer

• Personalis to Present at the 23rd Annual Needham Virtual Growth Conference

  12/28/2020

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of

• Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

  12/17/2020

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive identification and characterization of cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA enables the development of new neoantigen-based diagnostic biomark

• Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

  12/17/2020

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis’ state-of-the-art tumor neoantigen prediction tool, SHERPA™, with mechanisms of immune evasion to better predict response to cancer therapy. NEOPS combines the tumor genomic and immune-related analytics of the Person

• Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

  11/18/2020

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.

• Personalis® to Present at the AMP Annual Meeting 2020

  11/16/2020

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT DxTM - at the virtual AMP Annual Meeting from Nov 16-20, 2020.

• Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

  11/9/2020

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11 th – 13 th . The comp